头孢地尔治疗重症监护病房多重耐药革兰阴性菌感染:证据综述
本综述总结了头孢地尔(cefiderocol)的微生物谱、药代动力学/药效学、疗效与安全性及真实世界证据。头孢地尔是首个获批的铁载体β-内酰胺类抗生素,对碳青霉烯耐药肠杆菌目(CRE)、难治性铜绿假单胞菌、鲍曼不动杆菌、嗜麦芽窄食单胞菌等具有活性。1期研究显示其可在肺上皮衬液中达到足够浓度,需根据肾功能调整剂量,包括肾功能亢进和接受连续性肾脏替代治疗(CRRT)的患者。随机双盲APEKS-NP 3期研究显示,在疑似或确诊革兰阴性菌所致医院获得性肺炎患者中,头孢地尔14天全因死亡率非劣于大剂量延长输注美罗培南。然而,在碳青霉烯耐药革兰阴性菌感染患者中进行的随机开放标签CREDIBLE-CR 3期研究显示,头孢地尔组全因死亡率数值高于最佳可用治疗(BAT),导致美欧处方信息加入警告。
要点
- 头孢地尔是首个获批的铁载体β-内酰胺类抗生素,对CRE(产丝氨酸和/或金属碳青霉烯酶)、难治性铜绿假单胞菌、鲍曼不动杆菌、嗜麦芽窄食单胞菌、无色杆菌属和伯克霍尔德菌属耐药株有活性。
- APEKS-NP 3期随机双盲研究显示,在疑似或确诊革兰阴性菌所致医院获得性肺炎患者中,头孢地尔14天全因死亡率非劣于大剂量延长输注美罗培南。
- CREDIBLE-CR 3期随机开放标签研究显示,在碳青霉烯耐药革兰阴性菌感染患者中,头孢地尔组全因死亡率数值高于BAT组,美欧处方信息因此加入警告。
- 1期研究显示头孢地尔在肺上皮衬液中达到足够浓度,需根据肾功能调整剂量,包括肾功能亢进和接受CRRT的患者;预计无临床显著药物相互作用。
- 商业药敏试验结果因准确性和可靠性问题应谨慎评估;真实世界证据提示头孢地尔可能在部分危重患者组(如COVID-19肺炎继发革兰阴性菌重叠感染需机械通气者、接受CRRT和/或ECMO者)有效。
适用人群与场景
- 重症监护病房中患有严重革兰阴性菌感染的重症患者。
- 碳青霉烯耐药革兰阴性菌感染的目标患者群体,包括医院获得性肺炎、血流感染/脓毒症或复杂性尿路感染的住院患者。
- 真实世界证据涉及的多重耐药和碳青霉烯耐药革兰阴性菌感染患者,如因COVID-19肺炎继发革兰阴性菌重叠感染需机械通气的患者,以及接受CRRT和/或ECMO的患者。
处置流程与药物剂量
- 头孢地尔需根据肾功能调整剂量,包括肾功能亢进和接受连续性肾脏替代治疗(CRRT)的患者。
研究设计与关键结果
- APEKS-NP 3期随机双盲研究:在疑似或确诊革兰阴性菌所致医院获得性肺炎患者中,头孢地尔对比大剂量延长输注美罗培南,14天全因死亡率非劣效。
- CREDIBLE-CR 3期随机开放标签、以病原体为重点的描述性研究:在碳青霉烯耐药革兰阴性菌感染目标患者群体中,头孢地尔组全因死亡率数值高于最佳可用治疗(BAT)组,导致美国和欧洲处方信息加入警告。
- 1期研究:头孢地尔在肺上皮衬液中达到足够浓度,需根据肾功能调整剂量,包括肾功能亢进和CRRT患者;预计无临床显著药物相互作用。
- 商业药敏试验结果因当前准确性和可靠性问题应谨慎评估。
- 真实世界证据提示头孢地尔可能在特定危重患者组中有效,如因COVID-19肺炎继发革兰阴性菌重叠感染需机械通气的患者,以及接受CRRT和/或ECMO的患者。
证据类型、等级与局限
- 证据类型:综述,汇总1期药代动力学研究、APEKS-NP 3期随机双盲研究、CREDIBLE-CR 3期随机开放标签描述性研究及真实世界证据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 头孢地尔可用于治疗多重耐药、碳青霉烯耐药、难治性或广泛耐药革兰阴性病原体感染(治疗选择有限时),但CREDIBLE-CR中全因死亡率数值高于BAT导致美欧处方信息加入警告。
- 使用头孢地尔时应根据肾功能调整剂量,包括肾功能亢进和接受CRRT的患者。
- 解读头孢地尔商业药敏试验结果时应谨慎,因当前存在准确性和可靠性问题。
- 真实世界证据提示头孢地尔可能在需机械通气的COVID-19肺炎继发革兰阴性菌重叠感染患者及接受CRRT和/或ECMO的患者中有效(作者综述结论)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Appropriate antibiotic treatment for critically ill patients with serious Gram-negative infections in the intensive care unit is crucial to minimize morbidity and mortality. Several new antibiotics have shown in vitro activity against carbapenem-resistant Enterobacterales (CRE) and difficult-to-treat resistant Pseudomonas aeruginosa. Cefiderocol is the first approved siderophore beta-lactam antibiotic with potent activity against multidrug-resistant, carbapenem-resistant, difficult-to-treat or extensively drug-resistant Gram-negative pathogens, which have limited treatment options. The spectrum of activity of cefiderocol includes drug-resistant strains of Acinetobacter baumannii, P. aeruginosa, Stenotrophomonas maltophilia, Achromobacter spp. and Burkholderia spp. and CRE that produce serine- and/or metallo-carbapenemases. Phase 1 studies established that cefiderocol achieves adequate concentration in the epithelial lining fluid in the lung and requires dosing adjustment for renal function, including patients with augmented renal clearance and continuous renal-replacement therapy (CRRT); no clinically significant drug-drug interactions are expected. The non-inferiority of cefiderocol versus high-dose, extended-infusion meropenem in all-cause mortality (ACM) rates at day 14 was demonstrated in the randomized, double-blind APEKS-NP Phase 3 clinical study in patients with nosocomial pneumonia caused by suspected or confirmed Gram-negative bacteria. Furthermore, the efficacy of cefiderocol was investigated in the randomized, open-label, pathogen-focused, descriptive CREDIBLE-CR Phase 3 clinical study in its target patient population with serious carbapenem-resistant Gram-negative infections, including hospitalized patients with nosocomial pneumonia, bloodstream infection/sepsis, or complicated urinary tract infections. However, a numerically greater ACM rate with cefiderocol compared with BAT led to the inclusion of a warning in US and European prescribing information. Cefiderocol susceptibility results obtained with commercial tests should be carefully evaluated due to current issues regarding their accuracy and reliability. Since its approval, real-world evidence in patients with multidrug-resistant and carbapenem-resistant Gram-negative bacterial infections suggests that cefiderocol can be efficacious in certain critically ill patient groups, such as those requiring mechanical ventilation for COVID-19 pneumonia with subsequently acquired Gram-negative bacterial superinfection, and patients with CRRT and/or extracorporeal membrane oxygenation. In this article, we review the microbiological spectrum, pharmacokinetics/pharmacodynamics, efficacy and safety profiles and real-world evidence for cefiderocol, and look at future considerations for its role in the treatment of critically ill patients with challenging Gram-negative bacterial infections.
参考来源
- Viale P, Sandrock CE, Ramirez P, et al. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence. Ann Intensive Care. 2023. PMID: 37322293. doi:10.1186/s13613-023-01146-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。